SHR9352
Appearance
![]() | |
Identifiers | |
---|---|
| |
PubChem CID | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H36N2OS2 |
Molar mass | 480.73 g·mol−1 |
3D model (JSmol) | |
| |
|
SHR9352 is a drug which acts as a potent and selective biased agonist at the μ-opioid receptor, selective for activation of the G-protein signalling pathway over β-arrestin 2 recruitment. It was structurally derived from oliceridine by replacing the benzylic side chain with a cyclised group, although only some compounds in the series retained the desired biased agonist profile, with some derivatives such as compound 12 being potent, unbiased μ-opioid full agonists.[1]
![](http://178.128.105.246/cars-http-upload.wikimedia.org/wikipedia/commons/thumb/e/eb/Li-compound12_structure.png/180px-Li-compound12_structure.png)
See also
[edit]References
[edit]- ^ Li X, He W, Chen Y, Yang G, Wan H, Zhang L, et al. (December 2017). "Discovery of SHR9352: A Highly Potent G Protein-Biased μ-Opioid Receptor Agonist". ACS Omega. 2 (12): 9261–9267. doi:10.1021/acsomega.7b01452. PMC 6645658. PMID 31457439.
External links
[edit]Media related to SHR9352 at Wikimedia Commons